Showing results (331-340 of 412) with videos related to

Sort By:
Pageof 42
Blood|March 25, 2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemiaRamiro Garzon, Michael Savona, Rachid Baz, et al.
Blood Cancer Journal|January 15, 2024
Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation riskAshwin Kishtagari, M A Wasay Khan, Yajing Li, et al.
Haematologica|September 6, 2015
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsTariq I Mughal, Nicholas C P Cross, Eric Padron, et al.
Immunohorizons|December 22, 2022
Acly Deficiency Enhances Myelopoiesis through Acetyl Coenzyme A and Metabolic-Epigenetic Cross-TalkDalton L Greenwood, Haley E Ramsey, Phuong T T Nguyen, et al.
Blood Advances|April 14, 2022
Patient-specific comorbidities as prognostic variables for survival in myelofibrosisAndrew L Sochacki, Cosmin Adrian Bejan, Shilin Zhao, et al.
Cancer Research|January 29, 2024
Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid LeukemiaAndrew J Monteith, Haley E Ramsey, Alexander J Silver, et al.
Blood Advances|March 20, 2024
Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activationJ Brett Heimlich, Pawan Bhat, Alyssa C Parker, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2024
Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignanciesChristian T Meyer, Brianna N Smith, Jing Wang, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
The Lancet. Haematology|May 8, 2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trialGuillermo Garcia-Manero, Gail Roboz, Katherine Walsh, et al.
Pageof 42